Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

98th Annual Meeting of the American Association for Cancer Research (AACR)

TORONTO, April 17, 2007 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") today announced presentation of research on their lead antisense and siRNA compounds at the 98th Annual Meeting of the AACR in Los Angeles, CA, April 14-18, 2007.

The first presentation titled, "Determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro and in vivo," was presented on April 15, 2007.

This research determined a new optimal dosing schedule of GTI-2040 and docetaxel, which resulted in greatly enhanced synergy when docetaxel was given 48 hours after GTI-2040 compared to concomitant administration. This strong synergy was seen in vivo even after a single dose of GTI-2040. The discovery that administration of GTI-2040 prior to docetaxel is associated with this synergy, possibly through a 'stressor' effect due to decreased levels of R2 target expression, may potentially apply to other GTI-2040 combinations as well. This new sequential dose strategy will be an important consideration to maximize efficacy in the GTI-2040 clinical program.

The second presentation titled, "siRNAs targeting the R2 subunit of human ribonucleotide reductase exhibit in vitro and in vivo antitumor activity," will be presented on April 17, 2007.

In this research, Lorus screened a series of siRNAs to select a lead drug candidate, siRNA-1284. siRNA-1284 demonstrated potent antiproliferative and antitumor activity both in vitro and in vivo, coinciding with specific target silencing. These data warrant further development of siRNA-1284 as an anticancer agent. Lorus is also pursuing other cancer targets with its siRNA platform technology to screen and evaluate novel siRNA drug candidates.

"The research announced today provides important supporting data for Lorus' drug development
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/24/2013)... 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the ... announced today that Dr. Robert Grieve , ... Jason Napolitano , executive vice president and chief financial ... which is being held May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... Just about any bodyweight training program includes a variety of ... Dallas, GA that uses a variety of bodyweight conditioning circuits ... used enough. , “The medicine ball pushup is ... By keeping your hands on a medicine ball, the core ... much harder than a standard pushup. This unique bodyweight chest ...
(Date:5/24/2013)... 24, 2013 For the second consecutive ... Fresh Express Café to treat Tabitha Meals on Wheels ... their door. More than 400 meal recipients recently enjoyed ... restaurants, along with the rest of a well-balanced, nutritious ... to partner with the Tabitha Meals on Wheels team,” ...
(Date:5/24/2013)... have today released updated guidelines on Hormone Replacement Therapy ... the benefits and the risks. The new guidelines appear ... published by SAGE. , Over the last 11 ... of youth" to being considered extremely risky and only ... of the Women,s Health Initiative (WHI) trial in 2002, ...
(Date:5/24/2013)... Bridal Buy , a leading wedding ... 2013 bridesmaid dresses are available in its wedding ... featured as fine fabrics, elegant beading, and exquisite embroidery. ... and an eye for detailed designs. However, our lace ... life from patterns and the hands of dressmakers,” said, ...
(Date:5/24/2013)... Psoriasis treatment cream has been released online for ... registered company is now offering its natural solution to ... infected skin. , Dermasis has launched its new psoriasis ... cream is designed to offer immediate relief to those ... red skin often caused by psoriasis outbreaks. This new ...
Breaking Medicine News(10 mins):Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:Dermasis Psoriasis Treatment Cream for Men and Women Released Online at HealthCareSupplementz.com 2
... , SAN DIEGO, July 21 ... Anakam.TFA(R) Two-Factor Authentication as the enterprise authentication tool for ... to help the VA provide more veteran-centric benefit and ... cost-effective citizen-facing two-factor authentication solution delivered through multiple channels ...
... , , , ... historic show of unity, advocates for all the health Millennium Development Goals ... commitments to health by chronically underfunding programs for AIDS, TB, maternal and ... globe. , , The coalition of ...
... , BALTIMORE, July 21 Stayhealthy, Inc., a leader ... take control of their health, and Innovative Wellness Solutions a leader ... have reached an agreement to bring a powerful new solution to ... , , Wellness in the workplace ...
... SHENZHEN, China, July 21 /PRNewswire-Asia-FirstCall/ -- ... the,Company has changed its name to "BioPharm Asia, Inc." ... place in the next three to four weeks,in accordance ... name change to BioPharm Asia, Inc. will be reflected ...
... , , MONROVIA, Calif., July ... developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that ... Division of Bioresearch Monitoring that the restrictions of the "integrity hold" put ... The removal of the integrity hold enables the FDA to resume ...
... , , NEW YORK, July 21 ... cleanse Food & Wine Magazine recently dubbed ... State by announcing today that it will offer free delivery to anywhere in ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090721/LA49137 ) , , ...
Cached Medicine News:Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 2Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 4Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 5Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 6Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 7Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 8Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 2Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 3Health News:Domain Registration Corp. Announces Name Change to 'BioPharm Asia, Inc.' 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 4Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 5Health News:BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 2Health News:BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 3
5mSports™ is the handheld version of 5 Minute Sports Medicine Consult, your favorite reference for on-field and off-field treatment of sports related problems....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... the essential information that every intern ... wards, including the neurologic history and ... neuroimaging techniques and diagnostic tools, and ... dizziness, and ataxia, acute vision loss, ...
... all-original guide prepared specifically for ... from "PocketMedicine/Internal Medicine", it will ... those training in the field, ... are frequently the first to ...
Medicine Products: